Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | DRD2 | P14416 | 1/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.73 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.73 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.73 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.73 |
| ▸ | HTR2A | P28223 | 1/20 | 0.73 |
| ▸ | HTR2C | P28335 | 1/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.73 |
| ▸ | HRH1 | P35367 | 1/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.73 |
| ▸ | DRD3 | P35462 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11392242 | 0.90 | ABCB11 (0.59) | ABCB11LMNACHRM2CYP3A4ADRA2A | |
| Thiotepa SCHEMBL4760 | 0.86 | ABCB11 (1.00) | ABCB11LMNACHRM2CYP3A4ADRA2A | |
| Thiotepa SCHEMBL28205621 | 0.82 | ABCB11 (0.92) | ABCB11LMNACHRM2CYP3A4ADRA2A | |
| Thiotepa SCHEMBL287064 | 0.82 | ABCB11 (0.92) | ABCB11LMNACHRM2CYP3A4ADRA2A | |
| SCHEMBL31153244 | 0.73 | LMNA (0.73) | ABCB11LMNACHRM2CYP3A4ADRA2A | |
| SCHEMBL3084917 | 0.72 | ABCB11 (0.71) | ABCB11LMNACHRM2CYP3A4ADRA2A | |
| Tepa SCHEMBL7918394 | 0.71 | ABCB11 (0.69) | ABCB11LMNACHRM2CYP3A4ADRA2A | |
| SCHEMBL434983 | 0.69 | HPGD (0.65) | ABCB11LMNACHRM2CYP3A4ADRA2A | |
| SCHEMBL6048121 | 0.69 | ABCB11 (0.33) | ABCB11LMNACHRM2CYP3A4ADRA2A | |
| SCHEMBL6041009 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756041-B1 | Polycationic compounds and uses thereof | POLYMEDIX INC (US) | 2013-08-07 | — | — | EP | claimed |
| US-8071569-B2 | Oxidized heparin fractions and their use in inhibiting angiogenesis | MOUSA SHAKER A (US) | 2011-12-06 | — | — | US | claimed |
| US-20110200673-A1 | OXIDIZED HEPARIN FRACTIONS AND THEIR USE IN INHIBITING ANGIOGENESIS | MOUSA SHAKER A | 2011-08-18 | — | — | US | claimed |
| US-20100298344-A1 | Polycationic Compounds And Uses Thereof | POLYMEDIX, INC. | 2010-11-25 | — | — | US | claimed |
| US-20060104944-A1 | Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use | PHARMACEUTICAL RESEARCH INSTITUTE AT ALBANY COLLEGE OF PHARMACY | 2006-05-18 | — | — | US | claimed |
| WO-2024129875-A1 | COMBINATION THERAPIES FOR TREATING CANCER | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023102379-A1 | COMBINATION THERAPY FOR CANCER TREATMENT | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230011378-A1 | Combination Therapy For Treatment Of Cancer | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2023-01-12 | — | — | US | disclosed |
| EP-4010081-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2022-06-15 | — | — | EP | disclosed |
| US-20210379047-A1 | Combination Therapies For Treating Cancer | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2021-12-09 | — | — | US | disclosed |
| EP-3873445-A1 | COMBINATION THERAPIES FOR TREATING CANCER | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2021-09-08 | — | — | EP | disclosed |
| WO-2021026349-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2021-02-11 | — | — | WO | disclosed |
| US-20090239811-A1 | POLYCATIONIC COMPOUNDS AND USES THEREOF | POLYMEDIX, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-7553876-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| WO-2007136635-A1 | ENHANCEMENT OF RADIATION THERAPY AND/OR CHEMOTHERAPY WITH ACID CERAMIDASE MODULATORS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2007-11-29 | — | — | WO | disclosed |
| EP-1756041-A2 | POLYCATIONIC COMPOUNDS AND USES THEREOF | Polymedix, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2007005670-A2 | NATURAL AND SYNTHETIC SULFOXIDE, SELENONE AND SELENOXIDE ANALOGS AND POLYMER CONJUGATED FORMS THEREOF FOR THE MODULATION OF ANGIOGENESIS | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20060104944-A1 | Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use | PHARMACEUTICAL RESEARCH INSTITUTE AT ALBANY COLLEGE OF PHARMACY | 2006-05-18 | — | — | US | disclosed |
| US-20060041024-A1 | Polycationic compounds and uses thereof | CELLCEUTIX CORPORATION | 2006-02-23 | — | — | US | disclosed |
| WO-2005123660-A2 | POLYCATIONIC COMPOUNDS AND USES THEREOF | POLYMEDIX, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298344-A1 | Polycationic Compounds And Uses Thereof | VEGFA, VHL, PGF | ABCB11 3197/4885LMNA 3716/4885CHRM2 4843/4885 |
| US-20230011378-A1 | Combination Therapy For Treatment Of Cancer | CDK9, KRAS, BRD9 | ABCB11 2662/4885LMNA 1620/4885CHRM2 4829/4885 |
| US-20090239811-A1 | POLYCATIONIC COMPOUNDS AND USES THEREOF | VEGFA, VHL, PGF | ABCB11 3197/4885LMNA 3716/4885CHRM2 4843/4885 |
| US-20060041024-A1 | Polycationic compounds and uses thereof | VEGFA, VHL, PGF | ABCB11 3197/4885LMNA 3716/4885CHRM2 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.